Indonesia becomes the 70th country to authorize Sputnik V

Indonesia becomes the 70th country to authorize Sputnik V

Total population of all countries where Sputnik V is approved for use now exceeds 4 billion people, which is more than half of the global population.

Moscow, August 25, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the approval of the Russian Sputnik V vaccine against coronavirus in the Republic of Indonesia.

Indonesia has become the 70th country in the world to register the Russian vaccine. Sputnik V was granted an emergency use authorization. Total population of all countries where Sputnik V is approved for use now exceeds 4 billion people, which is more than half of the global population.

Real world data obtained during vaccination with Sputnik V in a number of countries (Argentina, San Marino, Serbia, Hungary, Bahrain, Mexico, UAE and others) demonstrate that Sputnik V is one of the safest and most effective vaccines against coronavirus. The Russian vaccine ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators.

Sputnik V has also been approved in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (entity of Bosnia and Herzegovina), Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San-Marino, Ghana, Syria, Kyrgyzstan, Guyana, Egypt, Honduras, Guatemala, Moldova, Slovakia, Angola, Republic of the Congo, Djibouti, Sri Lanka, Laos, Iraq, North Macedonia, Kenya, Morocco, Jordan, Namibia, Azerbaijan, Philippines, Cameroon, Seychelles, Mauritius, Vietnam, Antigua and Barbuda, Mali, Panama, India, Nepal, Bangladesh, Turkey, Albania, Maldives, Ecuador, Brazil, Nigeria and Chile.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said:

“Indonesia is one the most populated nations in Asia and inclusion of Sputnik V in the national vaccine portfolio will provide for using one of the safest and most effective vaccines in the world. Sputnik V is based on a proven human adenoviral vectors platform and is successfully used in over 50 countries. Approval in Indonesia is based on the results of a comprehensive assessment of the vaccine and will make an important contribution in country’s fight against the pandemic.”

Sputnik V has a number of key advantages:

·        Efficacy of Sputnik V is 97.6% based on the analysis of data on the coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021;

·        The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.

·        Sputnik V has pioneered the use of heterogeneous boosting (two different vectors for the two shots in a course of vaccination among COVID vaccines). This approach provides for immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

·        The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.

·        There are no strong allergies caused by Sputnik V.